{"id":52160,"date":"2024-07-26T07:53:30","date_gmt":"2024-07-26T07:53:30","guid":{"rendered":"https:\/?p=52160"},"modified":"2024-07-26T19:02:36","modified_gmt":"2024-07-26T19:02:36","slug":"how-astrazenecas-q2-2024-earnings-impact-its-stock-performance","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/","title":{"rendered":"How AstraZeneca&#8217;s Q2 2024 Earnings Impact Its Stock Performance"},"content":{"rendered":"<p><span style=\"font-weight: 400;\"><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/AZN\">AstraZeneca (AZN)<\/a> released its Q2 2024 earnings report yesterday which showcases significant growth across various revenue streams. The report highlights the company&#8217;s strong financial performance and an upgraded guidance for FY 2024. This article delves into the key insights from AstraZeneca&#8217;s Q2 report, its positive and negative implications for investors, and Stock Target Advisor&#8217;s analysis.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Key Insights from AstraZeneca&#8217;s Q2 Report:\u00a0<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">AstraZeneca&#8217;s Q2 2024 earnings report reveals robust financial growth, driven by substantial increases in product sales and alliance revenue. Here are the key highlights:<\/span><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\"><strong>Total Revenue:<\/strong> Increased by 13% (17% at CER) to $12,938 million, with significant contributions from oncology, cardiovascular, renal, and metabolism (CVRM), and respiratory and immunology (R&amp;I) therapies.<\/span><\/li>\n<li><span style=\"font-weight: 400;\"><strong>Product Sales:<\/strong> Rose by 14% (18% at CER) to $12,452 million, driven by strong demand for key products like Tagrisso, Farxiga, and Imfinzi.<\/span><\/li>\n<li><span style=\"font-weight: 400;\"><strong>Alliance Revenue:<\/strong> Increased by 42% to $482 million, primarily due to the strong performance of Enhertu and Tezspire.<\/span><\/li>\n<li><span style=\"font-weight: 400;\"><strong>Core EPS:<\/strong> Decreased by 8% (3% at CER) to $1.98, mainly due to gains recognized in the prior year from disposals and contractual updates.<\/span><\/li>\n<li><span style=\"font-weight: 400;\"><strong>Interim Dividend:<\/strong> Increased by 7 cents to $1.00.<\/span><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/\"><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter wp-image-52162 size-full\" src=\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2024\/07\/sta-stock-chart-widget-67.png\" alt=\"AZN stock chart widget\" width=\"522\" height=\"666\" srcset=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/07\/sta-stock-chart-widget-67.png 522w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/07\/sta-stock-chart-widget-67-235x300.png 235w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/07\/sta-stock-chart-widget-67-118x150.png 118w\" sizes=\"(max-width: 522px) 85vw, 522px\" \/><\/a><\/p>\n<h2><strong>Positive Implications for Investors:\u00a0<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">AstraZeneca&#8217;s Q2 2024 results present several positive aspects that are likely to benefit investors:<\/span><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\"><strong>Strong Revenue Growth:<\/strong> The company&#8217;s total revenue grew by 18% in H1 2024, driven by significant increases across key therapeutic areas.<\/span><\/li>\n<li><span style=\"font-weight: 400;\"><strong>Upgraded Guidance:<\/strong> AstraZeneca has upgraded its FY 2024 guidance, now expecting total revenue and core EPS to grow by a mid-teens percentage.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<h2><strong>Negative Implications for Investors:\u00a0<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Despite the strong performance, there are a few concerns for investors to consider:<\/span><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\"><strong>Decreased Core EPS:<\/strong> The 8% decrease in core EPS (3% at CER) is a notable drawback, primarily attributed to prior-year gains that were not replicated in 2024.<\/span><\/li>\n<li><span style=\"font-weight: 400;\"><strong>Currency Impact:<\/strong> AstraZeneca&#8217;s revenue and EPS are susceptible to foreign exchange fluctuations, which could negatively impact financial performance if adverse currency movements persist.<\/span><\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<h2><strong>Stock Target Advisor&#8217;s Analysis on AstraZeneca:\u00a0<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\"><a href=\"https:\/\/www.stocktargetadvisor.com\/\">Stock Target Advisor<\/a>&#8216;s analysis of AstraZeneca is bullish, supported by 12 positive signals and 5 negative signals. Key positive aspects include:<\/span><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Superior Risk-Adjusted Returns<\/span><\/li>\n<li><span style=\"font-weight: 400;\">High Dividend Returns:\u00a0<\/span><\/li>\n<li><span style=\"font-weight: 400;\">Superior Earnings and Revenue Growth<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">However, there are a few cautionary points:<\/span><\/p>\n<ul>\n<li><span style=\"font-weight: 400;\">Overpriced Valuation<\/span><\/li>\n<li><span style=\"font-weight: 400;\">High Leverage<\/span><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/pricing\"><img decoding=\"async\" class=\"aligncenter wp-image-51310 size-full\" src=\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2024\/07\/CTA-for-STA-1.jpg\" alt=\"STA's CTA\" width=\"1200\" height=\"350\" srcset=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/07\/CTA-for-STA-1.jpg 1200w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/07\/CTA-for-STA-1-300x88.jpg 300w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/07\/CTA-for-STA-1-1024x299.jpg 1024w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/07\/CTA-for-STA-1-150x44.jpg 150w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/07\/CTA-for-STA-1-768x224.jpg 768w\" sizes=\"(max-width: 709px) 85vw, (max-width: 909px) 67vw, (max-width: 1362px) 62vw, 840px\" \/><\/a><\/p>\n<h2><strong>Conclusion:\u00a0<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">AstraZeneca&#8217;s Q2 2024 earnings report underscores its strong financial performance and growth prospects, driven by robust product sales and strategic alliances. Investors should consider these factors while assessing AstraZeneca&#8217;s stock for their portfolios.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca (AZN) released its Q2 2024 earnings report yesterday which showcases significant growth across various revenue streams. The report highlights the company&#8217;s strong financial performance&#8230;<\/p>\n","protected":false},"author":17,"featured_media":52163,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-52160","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>How AstraZeneca&#039;s Q2 2024 Earnings Impact Its Stock Performance | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How AstraZeneca&#039;s Q2 2024 Earnings Impact Its Stock Performance\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca (AZN) released its Q2 2024 earnings report yesterday which showcases significant growth across various revenue streams. The report highlights the company&#8217;s strong financial performance...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-26T07:53:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-26T19:02:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/07\/STAs-Blog-Images-88.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Muzzammil Ahmad\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/Muzzammil625\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Muzzammil Ahmad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/\"},\"author\":{\"name\":\"Muzzammil Ahmad\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\"},\"headline\":\"How AstraZeneca&#8217;s Q2 2024 Earnings Impact Its Stock Performance\",\"datePublished\":\"2024-07-26T07:53:30+00:00\",\"dateModified\":\"2024-07-26T19:02:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/\"},\"wordCount\":383,\"commentCount\":1,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/\",\"name\":\"How AstraZeneca's Q2 2024 Earnings Impact Its Stock Performance | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2024-07-26T07:53:30+00:00\",\"dateModified\":\"2024-07-26T19:02:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How AstraZeneca&#8217;s Q2 2024 Earnings Impact Its Stock Performance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\",\"name\":\"Muzzammil Ahmad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"caption\":\"Muzzammil Ahmad\"},\"description\":\"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/\",\"https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625\"],\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How AstraZeneca's Q2 2024 Earnings Impact Its Stock Performance | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/","og_locale":"en_US","og_type":"article","og_title":"How AstraZeneca's Q2 2024 Earnings Impact Its Stock Performance","og_description":"AstraZeneca (AZN) released its Q2 2024 earnings report yesterday which showcases significant growth across various revenue streams. The report highlights the company&#8217;s strong financial performance...","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2024-07-26T07:53:30+00:00","article_modified_time":"2024-07-26T19:02:36+00:00","og_image":[{"width":1200,"height":628,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/07\/STAs-Blog-Images-88.jpg","type":"image\/jpeg"}],"author":"Muzzammil Ahmad","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/Muzzammil625","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Muzzammil Ahmad","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/"},"author":{"name":"Muzzammil Ahmad","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8"},"headline":"How AstraZeneca&#8217;s Q2 2024 Earnings Impact Its Stock Performance","datePublished":"2024-07-26T07:53:30+00:00","dateModified":"2024-07-26T19:02:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/"},"wordCount":383,"commentCount":1,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/","name":"How AstraZeneca's Q2 2024 Earnings Impact Its Stock Performance | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2024-07-26T07:53:30+00:00","dateModified":"2024-07-26T19:02:36+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/how-astrazenecas-q2-2024-earnings-impact-its-stock-performance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"How AstraZeneca&#8217;s Q2 2024 Earnings Impact Its Stock Performance"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8","name":"Muzzammil Ahmad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","caption":"Muzzammil Ahmad"},"description":"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.","sameAs":["https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/","https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625"],"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/52160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=52160"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/52160\/revisions"}],"predecessor-version":[{"id":52164,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/52160\/revisions\/52164"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/52163"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=52160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=52160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=52160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}